MAR 31, 2015 | 14:10 EDT
Ladenburg said Teva's (TEVA) deal for Auspex (ASPX) results in a payment of approximately $50M to Concert Pharmaceuticals (CNCE) related to a licensing pact signed in 2011 while it also "underscores and validates" the potential of deuterium-based chemistry. The firm maintains its Buy rating and $26 price target on Concert shares.
Jazz and Avanir need to kick it into high gear. It doesn't take that long to move from the close of phase 2 to phase 3. These companies are the slowest in getting things done. Expedited pathways? Nothing but lies. It's taking as long as any other average biotech.
This is #$%$. This stock has fallen enough. JAZZ & AVNR better work out :0(
She works for the company with the ticker symbol "ABC". She says they only hear about drugs moving into phase 3 because that's when they begin patient programs for the drugs. That's all the info I have right now. She also said Celgene with have 4 drug approvals between June & July.